HOMOHARRINGTONINE - PERSPECTIVES ON AN ACTIVE NEW NATURAL PRODUCT

被引：33

作者：

ODWYER, PJ ^{[1
]}

KING, SA ^{[1
]}

HOTH, DF ^{[1
]}

SUFFNESS, M ^{[1
]}

LEYLANDJONES, B ^{[1
]}

机构：

[1] NCI, DIV CANC TREATMENT, INVEST DRUG BRANCH, CANC THERAPY EVALUAT PROGRAM, BETHESDA, MD 20205 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 1986年 / 4卷 / 10期

关键词：

D O I：

10.1200/JCO.1986.4.10.1563

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1563 / 1568

页数：6

共 47 条

[1]

AJANI JA, 1986, CANCER TREAT REP, V70, P375

[2]

[Anonymous], 1977, CHIN MED J, V3, P319

[3]

[Anonymous], 1976, CHIN MED J, V2, P263

[4]

ARLIN Z, 1985, P AN M AM SOC CLIN, V4, P173

[5] CYTOTOXICITY AND CELL-CYCLE SPECIFICITY OF HOMOHARRINGTONINE [J].

BAASKE, DM ;

HEINSTEIN, P .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1977, 12 (02) :298-300

[6]

BOYD AW, 1984, BLOOD, V63, P384

[7]

CHOU TC, 1983, CANCER RES, V43, P3074

[8]

COBB WR, 1983, CANCER TREAT REP, V67, P173

[9]

COONLEY CJ, 1983, CANCER TREAT REP, V67, P693

[10] INHIBITION OF TRANSLATION IN EUKARYOTIC SYSTEMS BY HARRINGTONINE [J].

FRESNO, M ;

JIMENEZ, A ;

VAZQUEZ, D .

EUROPEAN JOURNAL OF BIOCHEMISTRY, 1977, 72 (02) :323-330

← 1 2 3 4 5 →